Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

121. Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density

Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density – TheNNTTheNNT Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or With Very Low Bone Density 100 for hip fracture In Summary, for those who took the bisphosphonates: Benefits in NNT 94% saw no benefit after 3 years of treatment 5% avoided

2011 theNNT

122. Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial Full Text available with Trip Pro

Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial FM is a condition that preferentially affects women. Sex hormones, and in particular oestrogens, have been shown to affect pain processing and pain sensitivity, and oestrogen deficit has been considered a potentially promoting factor for FM. However, the effects of oestrogen treatment (...) in patients suffering from FM have not been studied. Here, we examined the effect of transdermal oestrogen substitution treatment on experimental as well as self-estimated pain in women suffering from FM.Twenty-nine post-menopausal women were randomized to either 8 weeks of treatment with transdermal 17β-oestradiol (50 µg/day) or placebo according to a double-blind protocol. A self-estimation of pain, a set of quantitative sensory tests measuring thresholds to temperature, thermal pain, cold pain

2011 EvidenceUpdates Controlled trial quality: predicted high

123. WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. (Abstract)

WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. hMG and recombinant FSH, have both been used successfully for controlled ovarian hyperstimulation in in vitro fertilization and embryo transfer (IVF-ET).To compare the effectiveness of hMG with rFSH in ovarian stimulation protocols in IVF or ICSI treatment cycles.We searched the Cochrane Menstrual Disorders and Subfertility Group trials register

2011 Cochrane

124. AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Menopause

AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Menopause 1 AACE Guidelines Neil F. Goodman, MD, FACE; Rhoda H. Cobin, MD, MACE; Samara Beth Ginzburg, MD; Ira A. Katz, MD, FACE; Dwain E. Woode, MD American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health care professionals in medical decision making for specific clinical conditions but are in no way a substitute for a medical (...) for, their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. Copyright © 2011 AACE.2 AACE Menopause Guidelines Revision Task Force Cochairpersons Neil F . Goodman, MD, F ACE Rhoda H. Cobin, MD, MACE Task Force Members Samara Beth Ginzburg, MD Ira A. Katz, MD, F ACE Dwain E. Woode, MD Reviewers Pauline M. Camacho, MD, F ACE JoAnn E

2011 American Association of Clinical Endocrinologists

125. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Full Text available with Trip Pro

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cotte FE, De Pouvourville G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of osteoporosis treatment with oral bisphosphonates focusing on the issue of poor persistence in post-menopausal women. The authors concluded that improving persistence with oral bisphosphonate was likely to improve health benefits and reduce costs compared to current levels of treatment adherence

2011 NHS Economic Evaluation Database.

126. Odanacatib for post-menopausal osteoporosis ? first or second line

Odanacatib for post-menopausal osteoporosis ? first or second line Odanacatib for post-menopausal osteoporosis – first or second line Odanacatib for post-menopausal osteoporosis – first or second line NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Odanacatib for post-menopausal osteoporosis – first or second line. Birmingham

2011 Health Technology Assessment (HTA) Database.

127. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Full Text available with Trip Pro

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L CRD summary The authors concluded that indirect treatment comparisons (...) indicated teriparatide, zoledronic acid and denosumab had the highest probabilities of being most efficacious for non-vertebral and vertebral fractures. In the absence of direct comparisons, the evidence presented may be the best available. However, the authors' conclusions should be considered tentative given limitations of the evidence and synthesis. Authors' objectives To compare the efficacy of nine osteoporosis medications for reducing fractures in post-menopausal women. Searching Seven databases

2011 DARE.

128. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. Full Text available with Trip Pro

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. Concerns regarding the risks associated with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use and increased interest in nonhormonal treatments with demonstrated efficacy for hot flashes.To determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother (...) of menopausal hot flashes.A multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel group trial that enrolled 205 women (95 African American; 102 white; 8 other) between July 2009 and June 2010.Women received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.Primary outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8. Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvement

2011 JAMA Controlled trial quality: predicted high

129. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Full Text available with Trip Pro

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available.To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin (...) -releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.The PROMISE-GIM6 (Prevention of Menopause Induced by Chemotherapy: A Study in Early Breast Cancer Patients-Gruppo Italiano Mammella 6) study, a parallel, randomized, open-label, phase 3 superiority trial, was conducted at 16 sites in Italy and enrolled 281 patients between October 2003 and January 2008. The patients were

2011 JAMA Controlled trial quality: predicted high

130. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 17, No. 1, pp. 23/24 DOI: 10.1097/gme.0b013e3181cdd4a7 * 2010 by The North American Menopause Society 5 Text printed on acid-free paper NAMS continuing medical education activity Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society This position (...) statement, which begins on page 25, has been designatedacontinuingmedicaleducation(CME)activityfrom The North AmericanMenopause Society(NAMS). GOAL To demonstrate an increase in, or affirmation of, current knowledge regarding the management of osteoporosis in postmenopausal women. LEARNING OBJECTIVES After reading this position statement, participants should be able to: & Describe the effect of menopause and aging on bone health. & Identify risk factors that contribute to fracture risk. & Discuss

2010 The North American Menopause Society

131. Alternatives to HRT for the Management of Symptoms of the Menopause

Alternatives to HRT for the Management of Symptoms of the Menopause Alternatives to HRT for the Management of Symptoms of the Menopause Scientific Impact Paper No. 6 September 2010Alternatives to HRT for the Management of Symptoms of the Menopause This is the second edition of this Opinion Paper, which was originally published in 2006. 1. Background Despite recent encouraging data regarding the safety of traditional hormone replacement therapy (HRT), women and their primary care practitioners (...) of the publication from four years ago, aims to provide the reader with state-of-the-art knowledge on alternatives to HRT for the management of menopausal symptoms. 2. Lifestyle measures There is some evidence that women who are more active tend to suffer less from the symptoms of the menopause. 1 However, evidence from randomised controlled trials concerning the effects of aerobic exercise on vasomotor and other menopausal symptoms is limited. 2 The evidence suggests that aerobic exercise can improve

2010 Royal College of Obstetricians and Gynaecologists

132. Herbal medicines for menopausal symptoms

Herbal medicines for menopausal symptoms Herbal medicines for menopausal symptoms | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Herbal medicines for menopausal symptoms Article Text Reprinted from DTB Herbal medicines for menopausal symptoms Reprinted from: DTB 2009;47:2–6 Abstract Many women are now using herbal medicines to try to relieve menopausal symptoms such as hot flushes and night sweats, in light of recent evidence suggesting that hormone

2010 Evidence-Based Nursing

133. Work and the Menopause: A Guide for Managers

Work and the Menopause: A Guide for Managers Work and the Menopause: A Guide for Managers Introduction: Older women workers Women comprise approximately half (47 percent) of the UK’s workforce. About 3.5 million are women aged 50 and over. Occupational health issues for older workers in general, and older women workers in particular, have often been ignored. Many of today’s women workers are, or will be, working though a rarely discussed stage of life: the menopause. The British Occupational (...) Health Research Foundation (BOHRF) commissioned researchers at the University of Nottingham, led by Professor Amanda Griffiths, to explore women’s experience of working through the menopause. The research aimed to explore women’s experiences of working through the menopause, and to provide information for employers, for women and for those who advise them. It is based on interviews with women in managerial and administrative roles in several sectors 1 , and on responses to over 900 questionnaires

2010 British Occupational Health Research Foundation

134. Women's Experience of Working through the Menopause

Women's Experience of Working through the Menopause Institute of Work, Health & Organisations http://www.nottingham.ac.uk/iwho Women’s Experience of Working through the Menopause Amanda Griffiths, Sara MacLennan & Yin Yee Vida Wong A Report for The British Occupational Health Research Foundation 2010 2 CONTENTS TERMS OF REFERENCE 4 ACKNOWLEDGEMENTS 4 AUTHORS 5 INSTITUTE OF WORK, HEALTH & ORGANISATIONS 5 1. EXECUTIVE SUMMARY 6 2. INTRODUCTION & BACKGROUND 8 3. OVERVIEW OF RESEARCH DESIGN 9 4 (...) . REVIEW OF PUBLISHED LITERATURE 10 4.1 The menopause and its reported effects on health and well-being 10 4.2 Work and the menopause 11 4.3 Disclosure 12 4.4 Treatments for the menopause 12 4.5 Summary 13 5. INTERVIEW STUDY 14 5.1 Interview design 14 5.2 Data collection 14 5.3 Measurement of menopausal status 14 5.4 Participants 15 5.5 Transcription 15 5.6 Data analysis 15 5.7 Inter-rater reliability 15 5.8 Interview study: Results - Themes 15 5.8.2 Cognitive and emotional response (attributed

2010 British Occupational Health Research Foundation

135. Evaluation of intervention research in weight reduction in post menopausal women

Evaluation of intervention research in weight reduction in post menopausal women Evaluation of intervention research in weight reduction in post menopausal women Evaluation of intervention research in weight reduction in post menopausal women Al Zadjali M, Keller C, Larkey LK, Albertini L CRD summary The review found that exercise when combined with hypocaloric diet or meal replacement therapy may reduce body weight and fat and improve insulin sensitivity, glycaemic control and cardio (...) approaches that addressed lifestyle behaviours and employed a combination of diet and exercise strategies. Funding Not stated. Bibliographic details Al Zadjali M, Keller C, Larkey LK, Albertini L. Evaluation of intervention research in weight reduction in post menopausal women. Geriatric Nursing 2010; 31(6): 419-434 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Evidence-Based Nursing; Female; Humans; Postmenopause; Weight Loss AccessionNumber 12011001797 Date

2010 DARE.

136. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis

Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A CRD summary This review concluded that black cohosh may reduce the frequency of vasomotor symptoms associated with menopause and that more studies were warranted on its (...) effectiveness and safety. The authors' conclusions appeared to reflect the evidence, but given the likelihood of biases in identifying relevant studies it was difficult to verify these conclusions. Authors' objectives To investigate the efficacy of preparations containing black cohosh on reduction of vasomotor symptoms associated with menopause. Searching English-language studies were identified through a search of PubMed, EMBASE and The Cochrane Library to January 2008. Search terms were reported

2010 DARE.

137. Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis

Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

138. [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women]

[Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Analisis coste-utilidad de los tratamientos farmacologicos para la prevencion de fracturas en mujeres con osteoporosis en Espana [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Analisis coste-utilidad de los tratamientos farmacologicos para la prevencion de fracturas en (...) mujeres con osteoporosis en Espana [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Imaz I, Rubio B, Lopez-Delgado ME, Amate JM, Gomez-Pajuelo P, Gonzalez-Enriquez J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Imaz I, Rubio B, Lopez-Delgado ME, Amate JM

2010 Health Technology Assessment (HTA) Database.

139. Women's Health Initiative randomised ontrolled trial: Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause

Women's Health Initiative randomised ontrolled trial: Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause Article Text Therapeutics Women's Health Initiative randomised ontrolled trial Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause S. Mitchell Harman Statistics from Altmetric.com Commentary on: Toh S , Hernández-Díaz S , Logan R

2010 Evidence-Based Medicine

140. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause Full Text available with Trip Pro

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause The authors further analyzed results from the Women's Health Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without medroxyprogesterone acetate, focusing on health benefits versus risks among women who initiated hormone therapy soon after menopause. Data from the Women's Health Initiative observational study (1993-2004) were included in some analyses for additional (...) precision. Results are presented here for incident coronary heart disease, stroke, venous thromboembolism, breast cancer, colorectal cancer, endometrial cancer, or hip fracture; death from other causes; a summary global index; total cancer; and total mortality. Hazard ratios for breast cancer and total cancer were comparatively higher (P < 0.05) among women who initiated hormone therapy soon after menopause, for both regimens. Among these women, use of conjugated equine estrogens appeared to produce

2009 EvidenceUpdates Controlled trial quality: uncertain